ReviewAnnals of medicine and surgery (2012)2026
Hyperuricemia in heart failure with preserved ejection fraction: pathophysiological insights and therapeutic perspectives - a narrative review.
Review in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure with preserved ejection fraction (HFpEF) constitutes a growing burden worldwide, with hyperuricemia emerging as a prominent comorbidity. This review explores the prevalence, pathophysiological mechanisms, and therapeutic implications of hyperuricemia in HFpEF. Epidemiological studies consistently demonstrate that elevated serum uric acid (SUA) levels are associated with an increased risk of cardiovascular events, hospitalizations, and mortality. Mechanistic insights highlight endothelial dysfunction, oxidative stress, myocardial fibrosis, and systemic inflammation as key contributors linking hyperuricemia to adverse cardiac remodeling. Pharmacological interventions, including xanthine oxidase inhibitors, uricosuric agents, and SGLT2 inhibitors, show promise in mitigating hyperuricemia and improving HFpEF outcomes. Despite emerging evidence, critical knowledge gaps persist regarding causality, therapeutic efficacy, and optimal patient selection. Future research should focus on targeted interventions, dynamic SUA monitoring, and the interplay between hyperuricemia, diabetes, and left ventricular dysfunction to enhance the management of HFpEF patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.